Search

Pesticides governance is at the centre of a thick web of interests and values. The use of pesticides is coessential to the prevailing model of agricultural production, thus playing an important role in the provision of stable food supplies globally. Pesticides are also a highly remunerative business: in 2019, the global pesticides market has reached a value of nearly 84.5 billion $. 1On the other hand, pesticides are chemical compounds that may pose substantial risks to both human health and the environment, including biodiversity. 2Hence, their regulation entails striking a delicate balance between political, economic and public health and environmental considerations. Critically, all three are heavily informed by scientific evidence, with the consequence that regulatory-scientific expertise plays a key role in pesticides’ legal and regulatory governance, in particular when it comes to their risk assessment.

The Dry Andes region of Argentina and Chile is characterized by a highly developed periglacial environment. In these arid or semi-arid regions, rock glaciers represent one of the main pieces of evidence of mountain creeping permafrost and water reserves in a solid state. However, their distribution, degree of activity, and response to global warming are not yet well understood. In this context, this work aims to show the potential of the Sentinel-1-based interferometric technique (DInSAR) to map active rock glaciers at a regional level. In particular, the paper presents an active rock glacier inventory for the study area, which covers approximately 40,000 km2, ranging from latitude 30°210S to 33°210S. A total of 2116 active rock glaciers have been detected, and their elevations show a high correlation with the west-east direction. This result was obtained by using only 16 interferometric pairs. Compared to other remote sensing classification techniques, the interferometric technique offers a means to measure surface displacement (active rock glacier). This results in a reliable classification of the degree of activity compared to other methods, based on geomorphological, geomorphometric, and/or ecological criteria. This work presents evidence of this aspect by comparing the obtained results with existing optical data-based inventories. We conclude that the combination of both types of sensors (radar and optical) is an appropriate procedure for active rock glacier inventories, as both mapping methodologies are complementary. © 2018 by the authors.

NRAS mutations occur in 3-5% of colorectal cancer. Differently from KRAS and BRAF mutations, the role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer (mCRC) has been investigated to a lesser extent. A retrospective series suggested the role of NRAS mutations as predictors of resistance to anti-EGFR monoclonal antibodies (MoAbs) in chemo-refractory patients with mCRC. In our study, KRAS codons 12, 13, 61 and BRAF codon 600 mutational status were evaluated in mCRCs referred to our Institution from 2009 to 2012. NRAS codons 12, 13 and 61 mutational status was analyzed in KRAS/BRAF wt patients. We collected pathological and clinical features in the overall population and outcome data in a subset of NRAS mutated chemo-refractory patients treated with anti-EGFR MoAbs in advanced lines. NRAS was mutated in 47/786 (6%) mCRCs. NRAS and KRAS mutated tumors did not show significant differences in terms of clinical and pathological characteristics, except for a lower prevalence of mucinous histology (p = 0.012) and lung metastases (p = 0.012) among NRAS mutated tumors. In the uni- and multivariate model, NRAS mutations were associated with shorter overall survival (OS) compared to all wt patients (median OS 25.6 vs 42.7 months; univ: HR = 1.91, 95% CI 1.39-3.86, p = 0.0013; multiv: HR = 1.75, 95% CI 1.1.3-2.72, p = 0.013). None of the chemo-refractory NRAS mutated patients evaluable for response to anti-EGFRs achieved response. In conclusion, NRAS mutations have a relevant incidence in patients with mCRC and showed an association with specific clinical and pathological features. NRAS mutations affect mCRC patients' prognosis and predict lack of response to anti-EGFRs.